Home Blog Page 1721

The Government of Angola Launches an International Public Tender for the Management of the Namibe Corridor

LUANDA, ANGOLA – EQS Newswire – 12 December 2025 – The Ministry of Transport of The Republic of Angola (www.MinTrans.gov.ao) has today launched, 5th December, the Public Tender for the Concession of the Right to Operate, Manage and Maintain the Namibe Corridor. Interested entities may submit their proposals until 4 May 2026.

The concession, with an initial duration of 30 years, extendable up to 50 years, covers the operation, management, maintenance and preservation of the Moçâmedes–Menongue Railway Line, including rolling stock, associated infrastructure, workshops and the training centre. It further encompasses the possibility of designing and constructing new sections, extensions and branch lines, as well as railway connections to the Republic of Namibia and, at a later stage, to the Republic of Zambia.

The Secretary of State for Land Transport, Jorge Bengue, noted at the launch event that the process constitutes a strategic opportunity for international operators with a proven track record in the railway sector. “The Namibe Corridor has the potential to strengthen Angola’s role as a regional logistics platform, enhance supply chains, foster new investments, and increase the competitiveness of exports. We anticipate a dynamic tender process with strong participation from established industry operators,” he stated.

Jorge Bengue further emphasised that Angola has carried out structural reforms in recent years that have strengthened legal certainty and created a more competitive business environment. The success of the concession of the Lobito Corridor has demonstrated the country’s capacity to implement partnership models that stimulate private investment and accelerate the modernization of transport infrastructure.

Individual companies or consortiums of competitors with proven experience in the management of railway infrastructure and freight operations are eligible to apply. The detailed technical and financial requirements are set out in the tender documents, which are available for a fee of USD 20,000, or the equivalent in kwanzas at the exchange rate of the National Bank of Angola at the time of the transaction.

The Namibe Corridor encompasses the Moçâmedes Railway, with a total length of 855 km, and the Port of Namibe, forming a strategic logistics axis for the export of minerals, ornamental stones, agricultural products, and other goods. The infrastructure allows for a theoretical capacity of up to 5 million tonnes per year, serving as a connection point for landlocked countries in the region, in coordination with the Lobito and Walvis Bay corridors.

This corridor also contributes to tourism development and regional integration, strengthening Angola’s position in Atlantic–Indian trade routes and consolidating the country as a significant commercial hub within the African context.

The issuer is solely responsible for the content of this announcement.

VinFast VF 8 – Crafted for high-expectation markets in the GCC

Premium design meets industry-leading warranty and long-term support


DUBAI, UAE – Media OutReach Newswire – 12 December 2025 – The Middle East’s electric vehicle market is still developing but advancing quickly. In the Gulf Cooperation Council (GCC) region, EV sales penetration doubled from about 2 per cent to roughly 4 per cent in just one year, placing the region among the fastest-growing EV markets globally. 91% of battery-electric vehicle owners here say they plan to buy another EV, above the global average of 87%.

VF 8 photo.jpg

Amid that backdrop, buyers are seeking vehicles that match or exceed the space, performance, and refinement expected from premium SUVs. VinFast VF 8 arrives as a direct response to these elevated expectations, combining sophisticated design, robust capability, and a comprehensive ownership framework built around long-term confidence.

The VF 8 is shaped by VinFast’s “Dynamic Balance” design philosophy, a deliberate interplay between flowing curves and precise, angular lines that creates a sense of energy and visual structure without sacrificing harmony. This design language feels both contemporary and enduring. The result is a vehicle that projects presence without aggression, offering an aesthetic that balances boldness with sophistication, qualities that resonate with Middle Eastern consumers who view their vehicles as reflections of personal standards.

Under the sculpted exterior lies engineering tuned for high-demand regional driving. The VF 8 Plus variant delivers all-wheel drive with up to 402 horsepower and 620 Nm of torque, accelerating from 0 to 100 kph in under 5.5 seconds. This translates to confident overtaking on high-speed highways, assured merging in dense urban traffic, and the capability to handle extended cruising. Range reaches up to 493 km (NEDC) in the Eco configuration, a practical threshold aligned with intercity travel patterns across the region.

The 15.6-inch infotainment display provides intuitive access to navigation and vehicle settings. Crucially for the region, dual-zone climate control paired with ventilated seats are essential features designed to maintain cabin comfort even during peak heat.

The VF 8 integrates a comprehensive suite of smart systems designed to reduce driver workload. Traffic Jam Assist manages stop-and-go driving in congested environments, easing the fatigue of gridlock. Highway Assist supports sustained motorway cruising, helping drivers maintain lane position during long-distance travel. These systems work together to create a driving experience that feels more secure and less demanding.

Where the VF 8 truly distinguishes itself is in VinFast’s approach to long-term ownership. Addressing anxieties around battery longevity and service maturity, VinFast offers what may be the industry’s most comprehensive warranty structure. The VF 8 comes with a 10-year/200,000-km vehicle warranty and a 10-year unlimited-kilometer battery warranty, and 5-year/100,000-km of free service, eliminating one of the primary concerns of electric vehicle ownership. It’s also supported by practical service infrastructure: mobile service capabilities bring maintenance to customers’ locations, while 24/7 roadside assistance ensures support is available whenever needed.

The VF 8 represents VinFast’s understanding that success in sophisticated markets like the GCC requires vehicles that genuinely align with how people live, drive, and make long-term decisions. For Middle Eastern buyers navigating the transition to electric mobility, the VF 8 offers confidence in all aspects: design, performance, comfort, and warranty support. From the first drive to years down the road, it’s an electric vehicle crafted to deliver peace of mind alongside capability.

Hashtag: #VinFast

The issuer is solely responsible for the content of this announcement.

Bybit Introduces BYUSDT, Allowing Easy Earn Assets to Function as Trading Margin While Retaining Yield

DUBAI, UAE, Dec. 12, 2025 /PRNewswire/ — Bybit, the world’s second-largest cryptocurrency exchange by trading volume, has launched BYUSDT, a proprietary token developed entirely in-house by Bybit and available exclusively to VIP users, allowing eligible participants to convert USDT Flexible Easy Earn balances into trading margin while continuing to earn yield.

BYUSDT represents a 1-to-1 claim on users’ USDT held in Flexible Easy Earn and carries a 100 percent collateral value ratio for margin trading within Bybit’s Unified Trading Account. The structure is designed to let VIP users keep their yield-generating position in place while deploying the same balance as trading margin, rather than choosing between liquidity and returns.

BYUSDT can be swapped at a fixed 1-to-1 rate with USDT Flexible Easy Earn positions with no lock-up period and no depegging, since the conversion rate remains constant. Bybit is waiving minting and redemption fees for a limited period after launch, although a service fee may apply when swapping or redeeming BYUSDT on the BYUSDT page, including during yield conversion. Manual USDT repayments in the Unified Trading Account using BYUSDT, as well as liquidation settlements, incur no fee and convert 1-to-1 back to USDT.

The yield mechanism for BYUSDT follows the same annual percentage rate structure as USDT Flexible Easy Earn, excluding any platform reward APR. Rewards accrue hourly based on effective BYUSDT holdings, and only balances held for the full hour are counted. Yield is distributed once per day, at around 12:30 a.m. UTC, and is paid in BYUSDT to the user’s Unified Trading Account. If a swapping fee applies, it also applies to the yield conversion.

The BYUSDT product will be available starting 2 p.m. UTC Dec. 12, enabling eligible VIP users to mint, hold and use BYUSDT in line with product terms and platform rules. A separate BYUSDT Trading Competition with a total prize pool of 700,000 USDT is scheduled to begin at 10 a.m. UTC Dec. 15. The competition is governed by independent campaign rules and eligibility criteria, and only trading activity during the official competition period will be counted toward rewards.

Restrictions apply. Full terms and conditions are available here.

Disclaimer: BYUSDT may be unavailable or restricted in certain jurisdictions due to regulatory requirements.

Bybit Introduces BYUSDT, Allowing Easy Earn  Assets to Function as Trading Margin While  Retaining Yield
Bybit Introduces BYUSDT, Allowing Easy Earn Assets to Function as Trading Margin While Retaining Yield

#Bybit / #TheCryptoArk / #IMakeIt

About Bybit

Bybit is the world’s second-largest cryptocurrency exchange by trading volume, serving a global community of over 70 million users. Founded in 2018, Bybit is redefining openness in the decentralized world by creating a simpler, open and equal ecosystem for everyone. With a strong focus on Web3, Bybit partners strategically with leading blockchain protocols to provide robust infrastructure and drive on-chain innovation. Renowned for its secure custody, diverse marketplaces, intuitive user experience, and advanced blockchain tools, Bybit bridges the gap between TradFi and DeFi, empowering builders, creators, and enthusiasts to unlock the full potential of Web3. Discover the future of decentralized finance at Bybit.com.

For more details about Bybit, please visit Bybit Press
For media inquiries, please contact: media@bybit.com
For updates, please follow: Bybit’s Communities and Social Media

Discord | Facebook | Instagram | LinkedIn | Reddit | Telegram | TikTok | X | Youtube

Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits

SHANGHAI, Dec. 12, 2025 /PRNewswire/ — On December 10, 2025, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (“Sanyou Bio”) and Wenzhou KanryBio Biotech Co., Ltd.  (“KanryBio”) announced a strategic collaboration agreement. The partnership will focus on the joint development of key reagents and products for biomarker assay kits. By integrating Sanyou Bio’s core strengths in innovative biologics discovery with KanryBio’s expertise in kit product development and manufacturing, the collaboration aims to provide global biopharmaceutical R&D clients with more efficient, precise, and reliable total solutions for biomarker detection, thereby accelerating drug development and companion diagnostic processes.

Biomarkers are playing an increasingly critical role in drug R&D, clinical diagnostics, and personalized medicine. This strategic partnership is built upon both parties’ deep understanding of industry trends and mutual recognition of each other’s technical prowess. Sanyou Bio will leverage its globally leading AI Super-Trillion-Level (AI-STAL) intelligent molecular library and integrated drug discovery platform to drive innovative discovery and optimization of high-performance antibodies and other key reagents targeting specific biomarkers. KanryBio will contribute its extensive experience in high-end analytical instruments, high-value consumables, and kit development, along with its international-standard production and quality control systems, to ensure scalable manufacturing, performance validation, and stable supply of the co-developed products.

Through deep synergy, this collaboration aims to create core value across multiple dimensions:

1. Accelerated R&D Cycles: Joint development will shorten the timeline from discovery to productization of high-performance biomarker detection reagents, helping pharmaceutical companies expedite patient stratification, efficacy evaluation, and companion diagnostic development.

2. Enhanced Product Competitiveness: Combining Sanyou Bio’s source innovation with KanryBio’s engineering and cost-control capabilities, the partners will create high-end, domestically produced assay kits with superior performance, stable supply, and higher cost-effectiveness, reducing dependence on imported products in certain fields.

3. New Market Expansion: By pooling market resources, both companies will jointly promote the co-developed kit products and solutions, offering superior options to biopharmaceutical companies, CROs, and diagnostic firms worldwide and jointly exploring the vast precision medicine market.

Dr. Linglong Zou, Chairman and CEO of KanryBio, stated: “We are thrilled to partner with Sanyou Bio. Their exceptional capabilities in ultra-large-capacity molecular libraries and intelligent screening are impressive. This collaboration provides KanryBio with a powerful innovation engine for the ‘upstream’ of kit product development. We believe the deep integration of ‘discovery + translation’ will enable us to respond rapidly to market needs and develop high-quality biomarker detection products that address real customer pain points, jointly advancing industry technology.”

Dr. Guojun Lang, Founder and CEO of Sanyou Bio, commented: “The collaboration with KanryBio is a significant extension of Sanyou Bio’s mission—’to make innovative biologics accessible to all’—into the field of precision diagnostics. KanryBio’s proven ‘hard strength’ in systematic kit development and production is widely recognized. This strategic synergy is a key step in connecting our molecular discovery capabilities with an industrial partner’s engineering platform. We expect this partnership will not only supply high-quality key reagents but also enable us to participate in creating final products that solve customer detection challenges, providing more robust tools for biopharmaceutical R&D and jointly empowering the upgrade of the industry chain.”

This strategic partnership marks a solid step for Sanyou Bio in deepening industrial collaboration and building core technological advantages. Both parties will use this collaboration as a starting point to continuously explore broader cooperation, striving to become trusted partners for global biopharmaceutical R&D enterprises.

About KanryBio Biotechnology
Wenzhou KanryBio Biotechnology Co., Ltd. (“KanryBio”) leverages the robust scientific and technological strengths of the Wenzhou Institute of the Chinese Academy of Sciences. The company specializes in the R&D, production, and sales of high-end analytical instruments, high-value consumables, and reagents, aiming to deliver solutions with highly automated and sensitive analytical detection capabilities. Through continuous technological innovation and product upgrading, KanryBio strives to reduce client R&D costs and improve production efficiency, forming a complete industrial chain integrating R&D, production, sales, and service.

Headquartered in Wenzhou, Zhejiang, its R&D center serves as the innovation engine, gathering industry professionals and advanced R&D/production equipment. The pilot production workshop has obtained ISO9001 quality management system certification, further solidifying KanryBio’s technological leadership and enabling more personalized and customized services and products for clients.

KanryBio is committed to developing electrochemiluminescence analysis platforms, cell sorting platforms, and intelligent laboratory automation platforms, with the goal of breaking foreign technology monopolies and becoming a globally recognized enterprise in the biopharmaceutical and healthcare services sectors.

Since its inception, KanryBio has been awarded numerous honors, including:

  • First Prize at the 2022 Wenzhou Global Elite Innovation & Entrepreneurship Competition Finals.
  • First Prize (Category) and Second Prize (Finals) at the 2023 “UCAS Cup” Innovation & Entrepreneurship Competition in Beijing.
  • Recognition as a Leading Talent Entrepreneurship Project in Longwan District, Wenzhou (2023) and Wenzhou City (2024).
  • Selection for the Zhejiang Province “Top-Tier Talent Entrepreneurship Project” (2025).

About Sanyou

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical enterprise driven by its super-trillion molecule library and artificial intelligence technology, with the mission of “making innovative biologics R&D easy for clients worldwide”. Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub. The company is centered on its AI-driven super-trillion antibody library (AI-STAL) and supported by its world-leading, integrated and intelligent R&D platform for innovative biologics development that seamlessly combines in silico and wet-lab capabilities. Sanyou drives the global development and industrialization of innovative new drugs through diversified business models. Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities. Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages. The company has filed over 130 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai “Specialized and Innovative” Enterprise, ISO9001, and ISO27001.

United Imaging Intelligence at RSNA 2025: Reshaping Medicine with AI Agents

SHANGHAI, Dec. 12, 2025 /PRNewswire/ — Under the theme “Imaging the Individual”, RSNA 2025 challenged the radiology community to push into new frontiers and close the gap between personalized care and global health disparities. This year, United Imaging Intelligence (UII), the AI-focused subsidiary of United Imaging Group, framed that vision with a timely question: “Agent Radiologist: Are We There Yet?” The company invited attendees to experience a new generation of AI agents capable of understanding, reasoning, and acting across the entire care pathway, bringing more precise and accessible healthcare within reach.

Digital Transformation in Action: Medical Imaging Powered by AI Agents

The question “Agent Radiologist: Are We There Yet?” was inspired by uAI Insight, a next-generation Imaging-to-Report AI agent making its North American debut. Drawing strong interest from visitors around the world, uAI Insight demonstrated how AI can elevate diagnostic workflows by integrating clinical reasoning directly into reporting. Powered by UII’s multimodal large models, integrating language, vision, and speech, the system recognizes complex patterns, correlates key findings, and generates structured reports with clarity and precision. Many attendees expressed strong interest in future collaboration with UII.

Within uAI Insight, the uAI Agent for Chest CT Reporting demonstrated the ability of detecting 73 thoracic diseases from a single scan with an average AUC of 95%. The uAI Agent for Brain MRI Reporting identified 47 neurological conditions from one scan. Together, these tools signal the next phase of medical AI as the field shifts from task automation toward intelligent human-AI partnership.


RSNA 2025 also marked the debut of the uAI Agent for Ultrasound, an embodied AI robotic-arm system that integrates autonomous scanning with AI-assisted diagnosis. Interpreting visual, tactile, and pressure cues in real time, the agent adjusted probe position and force with precision, offering a gentler and more personalized patient experience.


A Unified Ecosystem of Intelligence: “Digitelligent Hospital” of Tomorrow

Across the booth, visitors saw how AI agents collaborate throughout the clinical workflow. uAI Avatar, an intelligent medical assistant, guided attendees through an end-to-end pre-diagnosis journey using natural conversation. Meanwhile, the uAI Agent for Hospital Management monitored imaging and reporting quality, assessed equipment performance, and transformed complex operational data into actionable insights. These agents spanned diagnostic imaging, surgical care, patient services, hospital operations, and clinical research, illustrating how AI can elevate care at every stage of the patient journey.

Expanding on these AI-driven interactions, UII introduced the concept of the “Digitelligent Hospital”. Built on UII’s multimodal medical large models, trained through years of clinical collaboration and supported by United Imaging’s comprehensive technology portfolio, this vision reflects an evolving ecosystem where digital and intelligent technologies reshape infrastructure, software, and operations. These models empower AI agents to analyze, reason, and make informed decisions, while embodied AI brings that intelligence into real-world tasks and natural human interaction. The result is a hospital that continuously learns, adapts, and evolves across all stages of care.

RSNA 2025 underscored a pivotal shift: medical AI is moving beyond traditional algorithms toward collaborative, autonomous AI agents that respond, adapt, and connect. With its rapidly expanding ecosystem, UII is leading the industrial innovation towards a more intelligent, virtualized, comprehensive, and personalized era of healthcare.

(Products and features referenced may not be available in all countries, and future availability cannot be guaranteed. Not all AI applications presented are CE-marked or FDA-cleared.)

NYSE Content Advisory: Pre-Market Update + Chipotle Mexican Grill Rings NYSE Bell Amid Expansion

NEW YORK, Dec. 12, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE Content Advisory: Pre-Market Update + Chipotle Mexican Grill Rings NYSE Bell Amid Its Expansion

Kristen Scholer delivers the pre-market update on December 12th

  • The Dow Jones is mixed early Friday, following a session where the S&P 500 and Russell 2000 hit record highs. Analysts say the rally’s broadening is a healthy sign for the bull market.
  • Wednesday’s quarter-point rate cut by the Federal Reserve lowered borrowing costs and boosted growth forecasts for next year, encouraging moves into cyclical stocks.
  • Shares of Chipotle rose 2.7% yesterday ahead of today’s announcement that it opened its 4,000th restaurant in Manhattan, Kansas. CEO Scott Boatwright will ring the NYSE opening bell to celebrate.

Opening Bell
Chipotle (NYSE: CMG) celebrates the opening of its 4,000th restaurant

Closing Bell
MSG Entertainment (NYSE: MSGE) rings the closing bell with the Harlem Globetrotters

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2844419/NYSE_Market_Update_Dec_12.mp4 

 

Global Attention: POGMENT Biomimetic Collagen “Stable Triple-Helix Breakthrough” –Unconventional and Astonishing

— LivingPhoenix Forum’s 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the “iPhone Moment for Extracellular Matrix Research”

CHENGDU, China, Dec. 12, 2025 /PRNewswire/ — LivingPhoenix Regenerative Technologies has drawn widespread international attention this November, presenting its world-first triple-helix biomimetic collagen across 12 high-level academic conferences. These events spanned over diverse fields including aesthetic medicine, regenerative medicine, biomaterials, and personal care. Leading academicians, renowned university professors, and industry representatives have unanimously endorsed the technology, recognizing it as a third-generation breakthrough that elevates collagen R&D from the eras of “animal extraction” and “genetic recombination” into a new age of “structural design”. This leap is hailed as the “iPhone moment” for area of extracellular matrix research.

From Beijing to Guangzhou and Changsha: Scientific Community Hails Disruptive Value of “Triple-Helix Structure”

On October 31st, the 3rd Badachu Aesthetic Medicine Industry Forum, organized by the Plastic Surgery Hospital of Chinese Medical Sciences Academy, opened grandly in Beijing. Qin Xingjiong, founder of Livingphoenix, delivered a keynote speech titled “From Compliance-First to Innovative Leap: How Biomimetic Collagen Releases New Quality Productive Forces within a Safety Framework.” The speech systematically outlined the company’s pathway to achieving technological leap while prioritizing regulatory, garnering high praise from the industry.

Next, at the “2025 10th Annual Medical Collagen Industry Academic Conference” held in Guangzhou, a distinguished gathering of representatives from leading universities—including South China University of Technology, Dalian University of Technology, Sichuan University, Lanzhou University, Donghua University, and Wuhan University—and enterprises spanning the entire industrial chain was convened. The forum was presided over by Professor Chen Xiaofeng from the School of Materials Science and Engineering at South China University of Technology, with honorary chairman held by Academician Liao Wanqing of the Chinese Academy of Engineering and Director of “Belt and Road” International Joint Laboratory for Mycology. As a representative innovative tech enterprise, Livingphoenix founder Qin Xingjiong presented a report titled “Aqueous Phase Polymeriization struction induced Stable Triple-Helix Biomimetic Collagen: From Structural Design to Biological Function Verification.” Academician Zhang Qiqing from the Chinese Academy of Medical Sciences provided live commentary, commented: “The scientific problem is precisely defined and thoroughly validated, forming a closed-loop chain from basic research to industrial application. This is a classical model for the integration of scientific innovation and industry.”

Academician Liao Wanqing of the Chinese Academy of Engineering was photographed alongside the company founder.
Academician Liao Wanqing of the Chinese Academy of Engineering was photographed alongside the company founder.

November 7, Changsha – The 2025 Scientists (International) Conference commenced grandly, drawing the global life sciences spotlight and over 3,000 professionals from more than ten countries. The event featured an illustrious lineup of speakers, including Nobel laureates Konstantin Novoselov (Physics, 2010), Brian K. Kobilka (Chemistry, 2012), Thomas C. Südhof (Physiology or Medicine, 2013), and Gregg L. Semenza (Physiology or Medicine, 2019).Qin Xingjiong, founder of Livingphoenix, delivered a presentation titled “From Follower to Leader: How Triple-Helix Biomimetic Collagen Breaks Industry Deadlocks – From Structural Innovation to Market Transformation, Deconstructing a Hundred-Billion-Dollar Arena with Innovative Solutions.” He introduced a new paradigm centered on “Structure-Driven Application,” which resonated strongly with the attending experts.

Global Expansion Accelerates: From Shanghai Forum to Indonesia Report, Original Chinese Innovation Takes Center Stage

November 11, Wenjiang, Chengdu – The “Forum on Regulatory Requirements and New Material Applications for Injectable Medical Aesthetic Products” was successfully held.

November 14-16, Shanghai – The 1st Global (Pan-Asia) Aesthetic Medicine & Healthcare Industry Summit and The 5th Yangtze Delta Medical Device Industry High-Quality Development Conference convened grandly in Shanghai. The event was co-organized by the Shanghai SongJianh area biomedical industry and the Shanghai Yangtze River Delta Medical Device Industry Development Association etc, co-hosted by Haohai Biomedical Technology Co. Ltd. and Chongqing Xingrong Plastic Surgery Hospital. Livingphoenix was invited to participate in a roundtable discussion chaired by Conference Chairman Mr. Wu Jianying, President of Haohai Biomedical Technology, and was officially inaugurated as a Council Member of the Global Medical Aesthetics and Health Organization. For a significant move to advance the integration of medicine and engineering, founder Qin Xingjiong was recommended for the position of Vice President and Secretary-General of the Medical Aesthetic Institutions Branch of the Chinese Association of Plastic and Aesthetics.The Pan-Asia forum attracted a vibrant assembly of over 3,000 experts, scholars, industry association representatives, and enterprise delegates from the global, fostering a dynamic atmosphere of exchange.

Subsequently, from the 19th to the 21st, the Livingphoenix team attended the PCT 2025 Personal Care Products Technology Convention in Guangzhou, where its POGMENT material and Smartender® Bouncy Bar garnered significant industry attention. This was immediately followed by the 2nd C-Beauty China Medical Aesthetics Industry Chain Forum from the 20th to the 22nd, where founder Qin Xingjiong took the stage again. He delivered a keynote address titled “From Follower to Leader: Decoding 45 Years of FDA Hurdles—How Triple-Helix Biomimetic collagen Breaks Deadlocks and Sets the Pace” and presided over the forum’s opening ceremony.

Breakthrough in Indonesia: Engaging Muslim Markets with High-Level Government Briefings

A particularly significant development occurred from November 23rd to 26th, when the Livingphoenix team traveled to Jakarta, Indonesia, for a dedicated promotion of its biomimetic collagen life materials tailored for Muslim markets. The team presented to Mr. Jeffri Ardiyanto, Director General of Pharmaceuticals and Medical Devices at the Indonesian Ministry of Health, detailing the global applicability, safety, and future potential of the technology. The presentation highlighted that Livingphoenix’s industry-leading ” PISA IN WATER” (Aqueous Phase Polymerization-Induced Self-Assembly) technology ensures superior biocompatibility and structural stability. A key advantage emphasized was the material’s specific suitability for Muslim-majority countries: it is non-animal-derived, free from ethical concerns, and fully compliant with Islamic Halal requirements. This innovation successfully overcomes the core limitations of traditional collagen in structural stability, biological activity, and material properties, achieving a full-chain leap from research and validation to industrialization. The visit garnered high-level recognition, with the team cordially received by the Special Envoy to the Indonesian President, General Paulus, and by Member of Parliament, Prof. Henry. These meetings underscored the strategic influence of this original Chinese technology in international markets.

Technical Foresight Elevated: Professor Xiao Jianxi of Lanzhou University

Notes—“Animal-Derived, Recombinant and Biomimetic Collagen Each Have Their Time.”

The technical dialogue reached its climax on November 27th at the MediCosme 2025 International Injectable Aesthetic Technology Innovation Conference. Livingphoenix founder Qin Xingjiong chaired the forum on “Collagen Regeneration Innovation and Technological Breakthroughs,” which featured presentations from leading experts including Professor Yao Min of Shanghai Ninth People’s Hospital, Dr. Huang Zhujie of Shiseido China, Professor Jiang Shibo of Jinbo Biotech, Dr. Li Haihang of Trautec, and Dr. Li Hongqiang of Feiman. The session comprehensively explored application scenarios, animal-derived collagen, recombinant collagen, and biomimetic collagen.

In a concluding keynote titled “Frontiers and Prospects in Collagen Preparation Technology,” Professor Xiao Jianxi of Lanzhou University delivered a powerful summation: “Animal-derived collagen is ancient yet modern, classic yet fashionable; recombinant collagen is youthful and vibrant, innovative and breakthrough; biomimetic collagen is in its budding era, full of future potential. Animal, recombinant, biomimetic – the collagen triple helix! Unity is strength.”

The forum also yielded promising prospects for collaboration. Professor Jiang Shibo, former Director of the Fudan University Institute of Microbiology and Chief Scientist at Jinbo Biotech, after attending Qin Xingjiong’s report on the structural design and functional validation of biomimetic collagen, remarked: “The presentation was excellent and highly enlightening. I look forward to potential future collaborations,” indicating a pathway to broader application scenarios for this original Chinese technology.

Subsequently, the founder attended the 16th China Medical City Medical Expo in Taizhou, where the Smartender® Biomimetic Collagen Bouncy Bar received widespread acclaim, further validating the product’s dual potential in both clinical and consumer markets.

Accolades and Advancements: Sichuan’s First Doctoral Innovation Stations Launched, Strengthening the Dual Engines of Basic Research and Commercialization

On November 3rd, the Livingphoenix Tech Doctoral Innovation Station, which integrates doctoral expertise from Peking University, the University of Science and Technology of China, the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, and the University of Tokyo, was officially designated as one of the first batch of Doctoral Innovation Stations in Sichuan Province. This initiative is a significant measure by the China Association for Science and Technology (CAST) to deepen integration between industry, academia, and research.Jing Ge, Vice President of the Sichuan Association for Science and Technology, emphasized the goal “to build highlands for originating technological innovation, incubators for talent development, bridges for industry-academia collaboration, and service hubs for the Association at the grassroots level.” Over the next three years, a “provincial-municipal coordination” mechanism will be deepened to achieve synergistic “high-low linkage” between Doctoral Innovation Stations and Academician (Expert) Workstations, thereby constructing a full-chain innovation ecosystem from basic research to commercialization.

Policy Engagement: Founder Leads Municipal CPPCC Research Initiative, Charting New Paths for University Tech Transfer

On November 18, a special research delegation led by Mr. Lü Haibo, Deputy Secretary-General of the Chengdu Municipal Committee of the CPPCC and Vice Chairperson of the Chengdu Committee of the Zhi Gong Party, visited the Chengdu Tianfu International Bio-Town. The focus was a thematic study on the “Collaborative Transformation Mechanism for University Scientific and Technological Achievements with Enterprises.”

The forum brought together professors from leading institutions—including the University of Electronic Science and Technology of China Medical School, West China Hospital of Sichuan University, the Medical School of Southwest Jiaotong University, and Chengdu University of Traditional Chinese Medicine—with key officials from the Chengdu High-tech Zone Bio-industry Bureau, the Tianfu International Bio-Town Management Committee, and Orinno Capital, alongside enterprise representatives.Discussions centered on critical issues such as building an integrated industry-academia-research ecosystem and defining the role of capital in facilitating technology transfer. A key consensus emerged: a multi-stakeholder, enterprise-led collaborative approach is essential to construct a veritable “expressway for technology” from the laboratory to the marketplace.

Livingphoenix founder Qin Xingjiong served as the lead author of the research report, contributing directly to the formulation of actionable recommendations for the transformation mechanism.

CIIE Global Launch: World’s First Triple-Helix Biomimetic Collagen Skincare Product “Smartender” Becomes Instant Hit

November 7, Shanghai – At the Sichuan Pavilion during the 8th China International Import Expo (CIIE), the Smartender Bouncy Bar made its remarkable global debut. As the world’s first functional skincare product based on a triple-helix structural design, it generated immense excitement among international buyers immediately upon launch.The product drew continuous crowds, with nearly 1,000 complimentary samples distributed entirely. Visitors from nearly 20 countries, including China, Japan, South Korea, Germany, the United States, and Australia, queued to experience it, offering enthusiastic feedback such as, “Good! Younger!” and “This is a game-changer!”During the expo, Mr. Chen Zhiyong, Vice Mayor of Chengdu, Sichuan Province, visited the Livingphoenix team to congratulate them on the global launch. He encouraged the enterprise to continue deepening its R&D efforts, accelerate the commercialization of achievements, and strive to build a “model for the integration of scientific innovation and industrial innovation,” thereby injecting new momentum into Chengdu’s and China’s life sciences sector on the global stage.

A Global Launch,the POGMENT-infused “Smartender® Bouncy Bar” premiered at the 8th CIIE.
A Global Launch,the POGMENT-infused “Smartender® Bouncy Bar” premiered at the 8th CIIE.

Epilogue:

Science reaches new heights, industry carries human warmth, and “Created in China” is accelerating its march to the center of the global stage.

Guided by its core principle of “Biomimetic Collagen and ECM Reconstruction,” Livingphoenix continues to advance the vision of “Cell House — Where Regeneration Begins.” Through the Human Collagen Freedom Initiative, it is now writing a new era in regenerative medicine for China.

Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy

NANTONG, China, Dec. 12, 2025 /PRNewswire/ — Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial (IIT) of RAG-18 at Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences in Beijing. This milestone marks a transformative moment in the fight against Duchenne Muscular Dystrophy (DMD), positioning RAG-18 as a potential game-changer for the field. By utilizing a novel saRNA mechanism to upregulate UTRN expression, RAG-18 represents a revolutionary therapeutic approach that aims to overcome the limitations of current treatments and could provide a universal solution benefiting all patients affected by this devastating condition.

The IIT is led by Professor Dai Yi, a distinguished expert in neuromuscular disorders and the Deputy Director of the Neurology Department at PUMCH. The study aims to assess RAG-18’s safety and pharmacokinetic profile while exploring its potential to improve muscle function in DMD patients. Professor Dai stated, “We are excited to begin this clinical trial with RAG-18, a cutting-edge therapeutic approach for treating DMD. We anticipate positive clinical results that could open up new, innovative treatment options for patients and significantly improve their quality of life.”

Dr. Long-Cheng Li, the Founder and CEO of Ractigen Therapeutics, shared his enthusiasm about the trial, stating, “Starting this study is a crucial step forward for RAG-18, emphasizing its unique role in overcoming the challenges of DMD. This treatment has the potential to address all genetic mutations related to DMD, illustrating RNA activation (RNAa) technology as a revolutionary method in clinical practice and offering hope for previously untreatable conditions.”

About RAG-18
RAG-18 is a first of its kind saRNA candidate designed to specifically target and activate UTRN gene expression in muscle cells via RNAa mechanism. The utrophin protein encoded by the UTRN gene is structurally and functionally similar to dystrophin, and its upregulation could potentially serve as a functional replacement for the missing dystrophin in DMD muscle cells, providing treatment for all DMD patients regardless of the specific mutation location.

Preclinical data indicate that RAG-18, delivered utilizing Ractigen’s proprietary LiCO™ (lipid-conjugated oligonucleotide) technology, has effectively upregulated UTRN expression, mitigated muscle damage and improved muscle function, demonstrating significant potential in treating DMD patients. RAG-18 received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) in 2024, underscoring its promise as a therapeutic option for patients with DMD.

About DMD
Duchenne Muscular Dystrophy (DMD) are severe genetic disorders caused by mutations in the dystrophin gene, leading to the absence or insufficiency of functional dystrophin protein. This protein is essential for muscle fiber stability. Without it, muscle cells are easily damaged and cannot repair themselves, resulting in progressive muscle weakness and degeneration. The dystrophin gene, the largest in the human body, contains 79 exons. Current disease-modifying therapeutic approaches for DMD include antisense oligonucleotides (ASO) mediated exon skipping, gene therapy, and gene editing, with exon skipping being the most common strategy. However, these treatments have significant limitations, highlighting the critical need for innovative therapies that target the root cause of DMD to provide more effective and long-lasting benefits for patients.

About RNAa
RNA activation is a clinically validated platform technology developed by Dr. Long-Cheng Li and his team. It utilizes saRNAs to target gene regulatory domains, activating gene expression and restoring therapeutic protein levels. This innovative technology holds vast potential for developing therapeutic drugs across various diseases, particularly where traditional methods fall short.

About Ractigen Therapeutics
Ractigen Therapeutics is a clinical-stage biopharmaceutical company innovating next-generation RNA therapeutics, with a primary focus on small activating RNAs (saRNAs) developed through its clinically validated RNA activation (RNAa) technology. Leveraging proprietary delivery platforms such as SCAD™, LiCO™, and GLORY™, Ractigen is advancing a robust pipeline addressing unmet medical needs in oncology, neurological diseases, and genetic disorders. Its versatile technologies also enable the rapid development of RNA-based solutions, including siRNAs, where applicable, to target life-threatening, fast-progressing conditions such as those in the CNS. Committed to scientific excellence and patient-centered innovation, Ractigen strives to transform healthcare through the power of RNA therapeutics. For more information, visit www.ractigen.com.